Women's Health & Gynecology Clinical Trials Update: Week 18, 2026
Published May 1, 2026 — 5 trials covered
By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia
This large Phase 3 trial led by Imperial College London is studying the effectiveness of the Gardasil 9 HPV vaccine when given after conservative treatment for cervical intra-epithelial neoplasia, a precancerous condition of the cervix. By vaccinating women soon after treatment, the study aims to reduce the risk of further HPV infections and prevent progression to cervical cancer. Results from over 1000 women enrolled internationally will help define better preventive strategies for cervical health.
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
This Phase 4 trial by the Mayo Clinic is testing tirzepatide, a medication, to see if it can reduce hot flashes and slow biological aging in postmenopausal women with obesity. Menopausal symptoms can be challenging, and this study explores a new approach that might improve quality of life while addressing underlying aging processes. The trial is recruiting participants in the United States and represents a potential new option for managing menopause-related issues.
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer (PANKU-GYN01)
This Phase 3 trial sponsored by Sichuan Baili Pharmaceutical is evaluating a new drug, BL-B01D1, against standard chemotherapy in patients whose ovarian cancer has returned and is resistant to platinum-based drugs. Since treatment options are limited for platinum-resistant ovarian cancer, this study could provide a valuable alternative to improve outcomes. The trial is currently recruiting 384 patients in China.
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology completed this Phase 2 trial testing whether bupropion hydrochloride can improve sexual desire in women who have had breast or gynecologic cancers. Sexual dysfunction is a common concern after cancer treatment, and this study offers hope for a treatment that could help without causing severe side effects. Results from 230 participants in the United States are now available for review.
Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
The University of Oklahoma is conducting a Phase 2 study to determine if giving antibiotics during labor can lower cesarean delivery rates among obese first-time mothers. Cesarean births carry higher risks, and obesity increases complications during delivery. This research involving about 787 participants in the United States could lead to safer labor practices for this high-risk group.
TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.